Transdermal Delivery of Physostigmine: Novel Approach to Sustained Drug Release| Chapter 3 | Pharmaceutical Science: New Insights and Developments Vol. 7

 

Transdermal delivery systems are self-contained, discrete dosage forms designed to deliver drugs across the intact skin at a controlled rate directly into the systemic circulation. Transdermal drug delivery systems have emerged as a promising alternative to conventional oral and parenteral routes. The present study focuses on the development of a Transdermal drug delivery system for physostigmine, aimed at overcoming hepatic first-pass metabolism and reducing dosing frequency compared to the conventional oral route.  The standard calibration curve of Physostigmine is constructed using Phosphate buffer pH7.4 as the medium, with Spectro photometric analysis performed at the drug's maximum absorbance of 255nm.Matrix-type transdermal patches were formulated using polymers such as Eudragit L 100, HPMCK4M, HPMC K15M Propylene glycol and Tween 80 were incorporated as the plasticiser and permeation enhancer, respectively, to improve patch flexibility and drug permeation through the skin. Transdermal patches were formulated using the solvent casting technique, enabling uniform film formation and drug dispersion. In vitro permeation studies were performed using a dialysis membrane (Hi-media) with a molecular weight of 12,000 Da to stimulate transdermal diffusion behaviour. The drug release data obtained from the study were fitted into various kinetic models-zero-order, first order, Higuchi and Korsemeyer-Peppas to evaluate the mechanism of drug release. Among the various formulations, the P6 patch exhibited the most promising results, achieving 96.5% of drug release over 12 hours period. The P6 formulation demonstrated a high regression coefficient (R2=0.9892) for the Korsemeyer-Peppas model with an n value of 0.6203, indicating a non-Fickian diffusion mechanism. Release kinetics analysis revealed that the drug release from P6 formulations followed Peppas model, indicating a diffusion-controlled mechanism. The findings of this study indicate that the developed physostigmine transdermal patch provides an effective alternative to oral administration by enabling sustained release, improving bioavailability, and potentially enhancing therapeutic outcomes.

 

Author(s) Details

B. RajaNarender

Department of Pharmaceutics, CVM College of Pharmacy, CVM College of Pharmacy, Velichala, Karimnagar, Telangana, India.

 

G. Madhuri
Department of Pharmaceutics, CVM College of Pharmacy, CVM College of Pharmacy, Velichala, Karimnagar, Telangana, India.

 

T. Gayathri
Department of Pharmaceutics, CVM College of Pharmacy, CVM College of Pharmacy, Velichala, arimnagar, Telangana, India.

 

Please see the book here:- https://doi.org/10.9734/bpi/psnid/v7/5663